RepliCel Life Sciences Inc., further to its news releases of April 22, 2020, and May 29, 2020, has received a temporary management cease trade order under National Policy 12-203 (Management Cease Trade Orders). It also arranged a private placement and a debt settlement, copies of which news releases are available on SEDAR. The company reports that its auditor has recently begun the audit of its annual financial statements for the year ended Dec. 31, 2019, though there can be no assurance that the audit will be completed by July 17, 2020.
We seek Safe Harbor.
